Biomet Expands Its Spine Play
Executive Summary
Biomet's recent acquisition of spine company InterporeCross expands its existing line of spine products but really is best seen as a follow-on to its recent buyout of its long-term alliance with German drug company Merck KGAA. Indeed, InterporeCross' major contribution in spine will come not in hardware, but in its strong orthobiologics program.You may also be interested in...
Biomet's Rebirth?
Dynamic Stabilization Rocks Spine
Biomet Deal Opens Door for PE Buyers
Need a specific report? 1000+ reports available
Buy Reports